[go: up one dir, main page]

TR199900729T2 - A��lar - Google Patents

A��lar

Info

Publication number
TR199900729T2
TR199900729T2 TR1999/00729T TR9900729T TR199900729T2 TR 199900729 T2 TR199900729 T2 TR 199900729T2 TR 1999/00729 T TR1999/00729 T TR 1999/00729T TR 9900729 T TR9900729 T TR 9900729T TR 199900729 T2 TR199900729 T2 TR 199900729T2
Authority
TR
Turkey
Prior art keywords
lar
sterol
antigen
relates
immunologically active
Prior art date
Application number
TR1999/00729T
Other languages
Turkish (tr)
Inventor
Garcon Nathalie
Friede Martin
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR199900729T2 publication Critical patent/TR199900729T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bu bulus sap, bir antijen, bir bagisikliksal aktif saponin fraksiyonu ile bir sterol içeren bir asi ile ilgilidir.This invention relates to an antigen, an immunologically active saponin fraction and a sterol containing a sterol.

TR1999/00729T 1996-10-05 1997-09-30 A��lar TR199900729T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9620795.6A GB9620795D0 (en) 1996-10-05 1996-10-05 Vaccines

Publications (1)

Publication Number Publication Date
TR199900729T2 true TR199900729T2 (en) 1999-07-21

Family

ID=10800990

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00729T TR199900729T2 (en) 1996-10-05 1997-09-30 A��lar

Country Status (19)

Country Link
EP (1) EP0939650A1 (en)
JP (1) JP2001501640A (en)
KR (1) KR20000048866A (en)
CN (1) CN1238696A (en)
AR (1) AR009958A1 (en)
AU (1) AU714930B2 (en)
BR (1) BR9711853A (en)
CA (1) CA2267191A1 (en)
CO (1) CO4910170A1 (en)
CZ (1) CZ116799A3 (en)
GB (1) GB9620795D0 (en)
HU (1) HUP9904549A3 (en)
IL (1) IL128985A0 (en)
NO (1) NO991524D0 (en)
NZ (1) NZ334734A (en)
PL (1) PL332633A1 (en)
TR (1) TR199900729T2 (en)
WO (1) WO1998015287A1 (en)
ZA (1) ZA978868B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050465B1 (en) * 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE122007000087I1 (en) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa ADJUVANCY SYSTEMS AND VACCINES
JP3282603B2 (en) 1999-01-28 2002-05-20 株式会社微生物化学研究所 Adjuvants and vaccines using them
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CZ303515B6 (en) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvant compositions
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
TR200200773T2 (en) 1999-09-24 2002-06-21 Nihon Nohyaku Co., Ltd Aromatic diamide derivatives, salts, chemical farming / horticulture
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
HK1047892B (en) * 1999-11-19 2009-01-09 Csl Limited Hcv vaccine compositions
AU2243801A (en) * 1999-12-08 2001-06-18 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
ATE513913T1 (en) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd IMMUNOGENIC POLYPEPTIDES ENCODED BY MAGE MINIGENE AND USES THEREOF
PT1889630E (en) 2000-10-18 2012-02-29 Glaxosmithkline Biolog Sa Vaccines comprising mage antigen linked to protein d fragment
CA2438960A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
ATE503493T1 (en) * 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL2368572T3 (en) 2005-11-04 2020-11-16 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
SI1962899T1 (en) 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0710210A2 (en) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A immunogenic composition, vaccine, methods for preparing the vaccine, and for preventing or treating staphylococcal infection, use of the immunogenic composition, and process for conjugating oligosaccharide or capsular polysaccharide
SG173363A1 (en) 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
CA2669209C (en) 2006-11-20 2016-01-26 Duecom Ab Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
EA021391B1 (en) 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Method of raising an immune response, vaccine composition, use thereof and kit
ES2626662T3 (en) 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vaccine comprising capsular polysaccharide conjugates of Streptococcus pneumoniae
BRPI0815199A2 (en) 2007-08-13 2015-03-31 Glaxosmithkline Biolog Sa Use of an antigen derived from plasmodium falciparum circumsporozyte protein
US10040825B2 (en) 2007-12-19 2018-08-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
EA023662B1 (en) 2009-02-10 2016-06-30 Новартис Аг Influenza vaccines with reduced amounts of squalene
ES2671880T3 (en) 2009-03-05 2018-06-11 Jenny Colleen Mccloskey Infection treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
US20130259948A1 (en) 2010-09-21 2013-10-03 National Institute Of Immunology Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CA2848611A1 (en) 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
BR112019003462A2 (en) 2016-08-23 2019-06-25 Glaxosmithkline Biologicals Sa fusion protein, polynucleotide, viral vector, pharmaceutical composition, use of a fusion protein, polynucleotide, viral vector or pharmaceutical composition, and method for treating or preventing viral hepatitis b infection or viral hepatitis c infection
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
JP7136777B2 (en) * 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム new process
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
IE20190085A3 (en) * 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
US11702674B2 (en) 2018-06-12 2023-07-18 Glaxosmithkline Biologicals Sa Simian adenovirus vectors comprising the ChAd-157 fiber protein
CN112601545A (en) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 Process and vaccine
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CN113573730A (en) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 Hepatitis B immunization protocols and compositions
US20230109193A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
DK0596032T4 (en) * 1991-07-25 2004-07-26 Idec Pharma Corp Induction of cytotoxic T lymphocyte responses
PT692974E (en) * 1993-03-29 2003-09-30 Pfizer CLOSTRIDAL VACCINES WITH MULTIPLE COMPONENTS USING SAPONIN ADJUVANTS
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine

Also Published As

Publication number Publication date
CA2267191A1 (en) 1998-04-16
HU9904549A (en) 2000-05-28
JP2001501640A (en) 2001-02-06
NZ334734A (en) 2000-05-26
CZ116799A3 (en) 1999-08-11
ZA978868B (en) 1999-04-06
AU4781297A (en) 1998-05-05
BR9711853A (en) 1999-08-24
IL128985A0 (en) 2000-02-17
AR009958A1 (en) 2000-05-17
CO4910170A1 (en) 2000-04-24
AU714930B2 (en) 2000-01-13
NO991524L (en) 1999-03-29
GB9620795D0 (en) 1996-11-20
NO991524D0 (en) 1999-03-29
PL332633A1 (en) 1999-09-27
CN1238696A (en) 1999-12-15
WO1998015287A1 (en) 1998-04-16
HUP9904549A3 (en) 2001-06-28
EP0939650A1 (en) 1999-09-08
KR20000048866A (en) 2000-07-25

Similar Documents

Publication Publication Date Title
TR199900729T2 (en) A��lar
BG101995A (en) Saponin and sterol-containing vaccines
TR199802423T2 (en) Concentrated antibody composition.
TR200000740T2 (en) Methods and compositions for whitening teeth.
TR200000573T2 (en) Poly-coated paper compounds
ITTO930789A1 (en) FIXING DEVICE FOR A SEAT COVER, PROCEDURE THAT USES THIS DEVICE AND SEAT OBTAINED IN ACCORDANCE WITH THIS PROCEDURE.
DE69010114D1 (en) Aligned slide holding device and slide arrangement therefor.
TR199600097A2 (en) Single lever mixing valve with an improved valve.
DE69006029D1 (en) Hydrocarbon fuel compositions and additives therefor.
TR199802557A3 (en) Process and arrangement for operating an offenend-twisting machine.
FR2733250B1 (en) ANTI-GP130 MONOCLONAL ANTIBODIES, AND USES THEREOF
TR199802486T2 (en) Enveloped goods.
NO892595L (en) PERFORING, TESTING AND SAMPLING TOOLS.
CR5406S (en) USEFUL LIGHTER
NO892760D0 (en) SAFETY VALVE TESTING DEVICE.
DE3486034D1 (en) SUBSTITUTED CINNAMYL-2,3-DIHYDROBENZOPYRANE AND CINNAMYLPHENOLE AS AN INFLAMMATORY-RESISTANT ACTIVE SUBSTANCE.
FI953093A7 (en) Methods for detecting and treating individuals with abnormal cells expressing HLA-A2/tyrosinase peptide antigens
NO901265D0 (en) GAS AND ODOR ABSORBING DEVICE.
DE68915112D1 (en) Spiro-isoquinoline-pyrrolidine tetrones and analogues thereof, useful as aldose reductase inhibitors.
DE3887536D1 (en) GAS MIXING DEVICE.
DE68914591D1 (en) Actuating lever and operating device.
DE68915011D1 (en) Gas cut-off device.
TR200001227T2 (en) Fuel composition and mixture.
DE68919463D1 (en) Brake shoe guide member and brake using this.
IT1227234B (en) TEXTILE CUTTING AND RETENTION DEVICE.